NCT03473730 2025-01-30
Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Completed
Clinical Trials
3 trialsNCT03035357 2024-05-03
Neoadjuvant Listeria or Daratumumab in Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT03177460 2024-05-03
Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Phase 1 Completed